8-K: Sangamo Therapeutics Files Chapter 11, Sells Assets to Eli Lilly

Sangamo Therapeutics has filed for Chapter 11 bankruptcy and completed the sale of substantially all its assets, including key technology platforms, to Eli Lilly and Company for $50 million.

Summary

• Sangamo Therapeutics, Inc. filed for Chapter 11 bankruptcy on June 23, 2026.
• The company has sold substantially all of its assets, including technology platforms like AAV capsid engineering and zinc finger protein technology, to Eli Lilly and Company for $50 million.
• The sale was approved by the Court on August 20, 2026, and completed on September 4, 2026.
• The company's common stock was suspended from trading on Nasdaq on May 5, 2026, and now trades on the OTCID Basic Market under the symbol SGMOQ.
• The Monthly Operating Report for July 2026 shows total assets of $155.1 million and total liabilities of $147.4 million.
• The company reported a net loss of $11.17 million for July 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the company's Chapter 11 bankruptcy filing and the sale of substantially all assets. The delisting from Nasdaq and trading on the OTC market further indicate severe financial distress.

Positives

• Completion of the sale of assets to Eli Lilly provides $50 million in cash and assumption of certain liabilities, offering some financial recourse.
• The company continues to operate as a debtor-in-possession under court jurisdiction, indicating an ongoing, albeit restructured, business operation.

Negatives

• The company has filed for Chapter 11 bankruptcy, signifying severe financial distress.
• Substantially all of the company's assets have been sold.
• The company's common stock has been delisted from the Nasdaq Capital Market and now trades on the OTCID Basic Market (SGMOQ), indicating a significant loss of market standing.
• The July 2026 Monthly Operating Report shows a net loss of $11.17 million for the month.
• Total liabilities ($147.4 million) exceed total assets ($155.1 million) as of July 31, 2026, though the net equity is positive at $7.74 million due to accounting methods in bankruptcy.

Risks

• Trading in the company's common stock is highly speculative and poses substantial risks.
• The trading prices of the common stock may bear little or no relationship to the actual recovery for holders in the Chapter 11 case.
• The Monthly Operating Report is unaudited, not prepared in accordance with U.S. GAAP, and subject to future adjustments, making it unreliable for investment decisions.
• There is no assurance that the financial information in the MOR is complete, and readers are cautioned not to place undue reliance on it.

Future Outlook

The filing primarily details past events and current financial status within bankruptcy proceedings. There is no forward-looking guidance provided regarding future operations or financial performance beyond the ongoing Chapter 11 process and asset sale.

Management Comments

• The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MOR, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company.
• The MOR is limited in scope, covers a limited time period and has been prepared solely for the purpose of complying with the reporting requirements of the Court.
• The MOR is not audited or reviewed by independent accountants, was not prepared in accordance with generally accepted accounting principles in the United States, is in a format prescribed by applicable bankruptcy laws or rules, and is subject to future adjustment and reconciliation.
• The Company urges extreme caution with respect to existing and future investments in its common stock.

Industry Context

StockSavvy.ai notes that Sangamo Therapeutics' Chapter 11 filing and asset sale to Eli Lilly reflect the high-risk, capital-intensive nature of the biotechnology sector, particularly for companies focused on novel therapeutic platforms. The sale of core technologies to a major pharmaceutical player is a common outcome in such situations, often signaling a pivot or wind-down for the original entity.

Legal Proceedings

• Chapter 11 Bankruptcy Case No. 26-10989 in the United States Bankruptcy Court for the District of Delaware.
• Court-supervised auction and sale of substantially all company assets to Eli Lilly and Company.

Stakeholder Impact

• Shareholders: The delisting and bankruptcy filing indicate a high likelihood of significant or total loss of investment.
• Creditors: The bankruptcy process will determine the recovery of prepetition and postpetition debts.
• Employees: The ongoing operations as debtor-in-possession suggest continued employment for some, but future employment is uncertain.
• Suppliers: Payments for postpetition goods and services are being made, but the long-term viability of the company is in question.

Next Steps

• The company will continue to operate as a debtor-in-possession under court supervision.
• The Chapter 11 proceedings will continue, potentially leading to a plan of reorganization or liquidation.
• Further financial reporting will be provided to the Court via Monthly Operating Reports.

Key Dates

Recommendation

The company is in Chapter 11 bankruptcy, has sold substantially all its assets, and its stock has been delisted from Nasdaq. This indicates a severe financial crisis with a very high probability of significant or total loss for existing shareholders. Investors should sell any holdings.

Keywords

Chapter 11, Bankruptcy, Asset Sale, Eli Lilly, Monthly Operating Report, Delisting, OTC Market